In Brief: Boston Scientific
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific: Revenues and operating results for the third quarter will "likely be flat or modestly up from the second quarter" due to "a more significant seasonal slow down in [medical] procedures worldwide than was expected," the firm announces Sept. 4. Due to the relatively lackluster third quarter, revenues and earnings for the year ending Dec. 31 "will likely be below the consensus of analysts' expectations," the firm states...
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.